Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm*, Nigel Armstrong, Bram L. T. Ramaekers, Xavier Pouwels, Shona Lang, Svenja Petersohn, Rob Riemsma, Gillian Worthy, Lisa Stirk, Janine Ross, Jos Kleijnen, Manuela A. Joore

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)655-667
Number of pages13
JournalPharmacoeconomics
Volume37
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • PHASE-III TRIAL
  • WEEKLY PACLITAXEL
  • VINFLUNINE PLUS
  • SUPPORTIVE CARE
  • OPEN-LABEL
  • CARCINOMA
  • MONOTHERAPY
  • MULTICENTER
  • DOCETAXEL

Cite this